Items where authors include "Vandevelde, C"

Article

Md Yusof, MY orcid.org/0000-0003-3131-9121, Arnold, J, Saleem, B et al. (5 more authors) (2023) Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. The Lancet Rheumatology, 5 (2). e88-e98. ISSN 2665-9913

Ye, W, Hackett, S, Vandevelde, C et al. (3 more authors) (2020) Comparing the visual analogue scale (VAS) and the numerical rating scale (NRS) in patient reported outcomes in psoriatic arthritis. The Journal of Rheumatology. jrheum.200928. ISSN 0315-162X

Marzo-Ortega, H, Tan, AL orcid.org/0000-0002-9158-7243, Bissell, L-A et al. (4 more authors) (2020) Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic. The Lancet Rheumatology, 2 (7). E386-E387. ISSN 2665-9913

Abignano, G, Fadl, N, Merashli, M et al. (4 more authors) (2019) A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service. Journal of the American Academy of Dermatology, 80 (6). pp. 1796-1798. ISSN 0190-9622

Al Arashi, W, Iñiguez Ubiaga, C, Hensor, EM orcid.org/0000-0002-5245-4755 et al. (6 more authors) (2018) Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort. Rheumatology Advances in Practice, 2 (2).

Conference or Workshop Item

Md. Yusof, MY, Arnold, J, Saleem, B et al. (5 more authors) (2022) OP0250 BREAKTHROUGH INFECTIONS AND PREDICTING SEVERE COVID OUTCOMES DURING RITUXIMAB THERAPY IN AUTOIMMUNE RHEUMATIC DISEASES. In: EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark.

Dubash, S orcid.org/0000-0002-9303-7122, Bryer, D, Fitton, J et al. (4 more authors) (2018) Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost effective strategy in spondyloarthritis. In: Annual European Congress of Rheumatology (EULAR 2018), 13-16 Jun 2018, Amsterdam, Netherlands.

Dubash, S orcid.org/0000-0002-9303-7122, Bryer, D, Fitton, J et al. (4 more authors) (2018) Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost effective strategy in spondyloarthritis. In: Eleventh International Congress on Spondyloarthritides, 04-06 Oct 2018, Gent, Belgium.

Proceedings Paper

Yusof, YM, Arnold, J, Saleem, B et al. (5 more authors) (2022) Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases. In: Arthritis and Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 1559-1560.